MA64619A1 - Protéine modifiée séparée vp1 de capside aav5 - Google Patents

Protéine modifiée séparée vp1 de capside aav5

Info

Publication number
MA64619A1
MA64619A1 MA64619A MA64619A MA64619A1 MA 64619 A1 MA64619 A1 MA 64619A1 MA 64619 A MA64619 A MA 64619A MA 64619 A MA64619 A MA 64619A MA 64619 A1 MA64619 A1 MA 64619A1
Authority
MA
Morocco
Prior art keywords
relates
efficiency
aav5
capsid
raav5
Prior art date
Application number
MA64619A
Other languages
English (en)
Inventor
Pavel Andreevich Iakovlev
Dmitry Valentinovich Morozov
Anna Nikolaevna Strelkova
Mariya Pavlovna Perepelkina
Pavel Mikhailovich Gershovich
Tatiana Evgenievna Shugaeva
Sergei Aleksandrovich Legotskii
Vladimirovich Alexander
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021124727A external-priority patent/RU2820088C1/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MA64619A1 publication Critical patent/MA64619A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention se rapporte au domaine de la thérapie génique et de la biologie moléculaire. Plus précisément, la présente invention concerne une protéine modifiée séparée vp1 de capside de virus adéno-associé de sérotype 5 (aav5), qui comprend une ou plusieurs substitutions d'acide aminé par rapport à la protéine vp1 de aav5 de type sauvage, qui augmentent l'efficacité de la transduction, qui augmentent l'efficacité d'emballage des génome viraux de aav avec des préparations à base de raav5, et qui augment l'efficacité de production (construction) d'un vecteur à base de virus adéno-associé de sérotype 5 recombinant (raav5); l'invention concerne également un capside et un vecteur à base de la vp1 susmentionnée, ainsi que leur utilisation.
MA64619A 2021-08-20 2022-08-21 Protéine modifiée séparée vp1 de capside aav5 MA64619A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2021124727A RU2820088C1 (ru) 2021-08-20 Выделенный модифицированный белок VPI капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе
PCT/RU2022/050257 WO2023022633A1 (fr) 2021-08-20 2022-08-21 Protéine modifiée séparée vp1 de capside aav5

Publications (1)

Publication Number Publication Date
MA64619A1 true MA64619A1 (fr) 2024-04-30

Family

ID=85240919

Family Applications (1)

Application Number Title Priority Date Filing Date
MA64619A MA64619A1 (fr) 2021-08-20 2022-08-21 Protéine modifiée séparée vp1 de capside aav5

Country Status (11)

Country Link
EP (1) EP4389759A1 (fr)
CN (1) CN117881689A (fr)
AR (1) AR126840A1 (fr)
AU (1) AU2022329630A1 (fr)
CA (1) CA3229587A1 (fr)
CO (1) CO2024001681A2 (fr)
EC (1) ECSP24013075A (fr)
IL (1) IL310961A (fr)
MA (1) MA64619A1 (fr)
TW (1) TW202315947A (fr)
WO (1) WO2023022633A1 (fr)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3431140A1 (de) 1984-08-24 1986-03-06 Behringwerke Ag, 3550 Marburg Enhancer fuer eukaryotische expressionssysteme
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE19827457C1 (de) * 1998-06-19 2000-03-02 Medigene Ag Strukturprotein von AAV, seine Herstellung und Verwendung
EP1453547B1 (fr) * 2001-12-17 2016-09-21 The Trustees Of The University Of Pennsylvania Sequences du serotype 8 du virus associe a l'adenovirus (aav), vecteurs les contenant et utilisations correspondantes
EP3693025B1 (fr) 2011-04-22 2021-10-13 The Regents of The University of California Virions de virus adéno-associé avec capside variant et procédés d'utilisation de ceux-ci
MY172457A (en) 2012-04-18 2019-11-26 Childrens Hospital Philadelphia Composition and methods for highly efficient gene transfer using aav capsid variants
CA3209883A1 (fr) * 2013-07-22 2015-01-29 The Children's Hospital Of Philadelphia Compositions et variants de virus adeno-associes, et methodes et utilisations pour un transfert de genes dans des cellules, des organes et des tissus
RU2751592C2 (ru) 2019-08-22 2021-07-15 Общество С Ограниченной Ответственностью "Анабион" Выделенный модифицированный белок VP1 капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе

Also Published As

Publication number Publication date
CN117881689A (zh) 2024-04-12
CO2024001681A2 (es) 2024-06-27
IL310961A (en) 2024-04-01
EP4389759A1 (fr) 2024-06-26
TW202315947A (zh) 2023-04-16
AR126840A1 (es) 2023-11-22
ECSP24013075A (es) 2024-03-01
CA3229587A1 (fr) 2023-02-23
WO2023022633A1 (fr) 2023-02-23
AU2022329630A1 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
MA51353B1 (fr) Sérotype du virus adéno-associé recombinant hybride entre aav9 et aavrh74 possédant un tropisme hépatique réduit
MA56142B1 (fr) Protéine modifiée séparée vp1 de capside de aav5
EP4218828A3 (fr) Capsides de variants de virus adéno-associés et leurs procédés d'utilisation
JP2020508685A5 (fr)
EP4272728A3 (fr) Capsides variantes de virus adéno-associés et leur utilisation pour inhiber l'angiogenèse
BR112021018776A2 (pt) Vetores de vírus adenoassociado recombinante
Chandler et al. Gene therapy for metabolic diseases
Koenig et al. Soil-borne rye mosaic and European wheat mosaic virus: two names for a furovirus with variable genome properties which is widely distributed in several cereal crops in Europe
MX2022013819A (es) Capsides de virus adeno-asociado 5 modificado y usos del mismo.
DE60227268D1 (de) Knockout-mutante von vaccinia-virus und verwendung davon
BR112023024375A2 (pt) Vírus adeno-associado recombinante tendo capsídeo variante e sua aplicação
Hahn et al. Viral FGARAT homolog ORF75 of rhesus monkey rhadinovirus effects proteasomal degradation of the ND10 components SP100 and PML
MA64619A1 (fr) Protéine modifiée séparée vp1 de capside aav5
EA202192819A1 (ru) Способы и композиции для экспрессии трансгена
MX2023012722A (es) Capsides de aav y usos de las mismas.
BR112023015769A2 (pt) Vetor de vírus adenoassociado de rna (raav) e usos do mesmo
AR123369A1 (es) VACUNA BASADA EN AAV5 PARA LA INDUCCIÓN DE INMUNIDAD ESPECÍFICA CONTRA EL SARS-CoV-2 Y/O LA PREVENCIÓN DE LA INFECCIÓN POR CORONAVIRUS RELACIONADA CON EL SARS-CoV-2
Dostálková et al. Mutations in the basic region of the Mason-Pfizer monkey virus nucleocapsid protein affect reverse transcription, genomic RNA packaging, and the virus assembly site
EA200601043A1 (ru) Промоторы для экспрессии в модифицированном вирусе осповакцины штамма анкара
MX2022012279A (es) Variantes de capsides de aav y usos de los mismos.
MX2022009252A (es) Proteinas de la capside de virus adeno-asociados modificadas para la terapia genica ocular y metodos de uso de las mismas.
Schön et al. Human endogenous retroviral long terminal repeat sequences as cell type-specific promoters in retroviral vectors
MA64618A1 (fr) Protéine modifiée séparée vp1 de capside aav9
Douar et al. Deleterious effect of peptide insertions in a permissive site of the AAV2 capsid
US20220307051A1 (en) A process for producing a plurality of neddylation site modified aav vectors